Cardiff Oncology Inc Sustainability Reports
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer patients. Its lead therapeutic candidate is onvansertib, a polo-like kinase 1 inhibitor evaluated in combination with other treatments across various oncology indications.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300AHOLZBHHYFWP04
FIGI: BBG001SLWWP7
2 reports from 2021 to 2023
